JosephHarryAntinMD
Hematology • Boston, MAHematologic Oncology
Professor of Medicine, Dana-Farber Cancer Institute
Dr. Antin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-4559Fax+1 617-632-5175- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1981 - 1983- Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Weill Cornell MedicineClass of 1978
Certifications & Licensure
MA State Medical License 1986 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2008-2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Boston Herald Castle Connolly, 2005
- Join now to see all
Clinical Trials
- Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
- Phase I Study of Sequential Cord Blood Transplants Start of enrollment: 2003 May 01
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsProphylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.Garcia, J., Kim, H., Murdock, H., Ansuinelli, M., Brock, J., Cutler, C., Gooptu, M., Ho, V., Koreth, J., Nikiforow, S., Romee, R., Shapiro, R., DeAngelo, D., Stone, R....> ;Blood Advances. 2024 Feb 27
- 1 citationsOpportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft.Jessica S Little, Rémy Duléry, Roman M Shapiro, Muneerah M Aleissa, Susan E Prockop, John Koreth, Jerome Ritz, Joseph H Antin, Corey Cutler, Sarah Nikiforow, Rizwan Ro...> ;Transplantation and Cellular Therapy. 2024 Feb 1
- 5 citationsPosttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.Katie Maurer, Vincent T Ho, Eno Inyang, Corey Cutler, John Koreth, Roman M Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Joseph H Antin, Catherine J Wu, Je...> ;Blood Advances. 2023 Aug 8
- Join now to see all
Journal Articles
- Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host DiseaseJoseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood
Abstracts/Posters
- Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T CellsJoseph H. Antin, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
- Graft Failure after Haploidentical Hematopoietic Stem Cell TransplantationJoseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
ASBMT NewsOctober 13th, 2018
Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study FindsFebruary 9th, 2017
Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study FindsFebruary 8th, 2017- Join now to see all
Grant Support
- A Randomized Trial Of Tac/Mtx/Bortezomib VS Tac/Mtxplacebo In Allogeneic HSCTNational Heart, Lung, And Blood Institute2011
- Novel Approaches To Graft-Versus-Host Disease PreventionNational Cancer Institute2009–2011
- Mechanisms Of GVHDNational Cancer Institute2009–2011
- Administrative CoreNational Cancer Institute2009–2011
- Random Trial Of CD8 T-Cell Depletion In PBSC TransplantationNational Heart, Lung, And Blood Institute2006–2010
- Novel Approaches To Ghvd PreventionNational Heart, Lung, And Blood Institute2007
- Mechanisms Of GVHDNational Heart, Lung, And Blood Institute2003–2007
- Randomized Trial Of CD8 T-Cell Depletion In PBSC Transp*National Heart, Lung, And Blood Institute2001–2005
- Use Of Unrelated Donors For Bone Marrow TransplantationNational Center For Research Resources1997–1999
- Phlebotomy For Research Studies After Marrow TransplantationNational Center For Research Resources1997–1999
- Core--Clinical Bone Marrow Transplant ProgramNational Cancer Institute1997
- Novel Therapy For Chronic Myelogenous LeukemiaNational Cancer Institute1993–1996
Professional Memberships
- Member
- American Society of Blood and Marrow TransplantationMember
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
